HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Abbas E. Abbas Larry R. Kaiser Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lambright, E. S. Articles by Kaiser, L. R. Search for Related Content PubMed PubMed Citation Articles by Lambright, E. S. Articles by Kaiser, L. R.

Ann Thorac Surg 1999;68:1756-1760
© 1999 The Society of Thoracic Surgeons

---

Original Articles

Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system

^a Thoracic Oncology Laboratory, Harrison Department of Surgical Research, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA

Address reprint requests to Dr Kaiser, General Thoracic Surgery, Hospital of the University of Pennsylvania, 6 Silverstein Pavilion, Philadelphia, PA 19104
e-mail: kaiser{at}mail.med.upenn.edu

Presented at the Thirty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 25–27, 1999.

Background. Herpes simplex virus (HSV)-1716, a replication-restricted herpes simplex virus type 1, has shown efficacy as an oncolytic treatment for central nervous system tumors, breast cancer, ovarian cancer, and malignant mesothelioma. We evaluated the efficacy of HSV-1716 in a murine lung cancer model, Lewis lung carcinoma.

Methods. Lewis lung carcinoma cells were infected with HSV-1716 and implanted in the flanks of mice at varying ratios of infected to uninfected cells. Tumor burden was assessed by measurement of the weight of the tumor nodule. The role of the immune system was examined by performing experiments in both immunocompetent and SCID mice. Tumors were implanted in the opposite flank to evaluate the vaccine effect.

Results. In immunocompetent and SCID animals, ratio of 1:10 (infected-to-uninfected) cells completely prevented tumor formation and ratio of 1:100 suppressed tumor growth. Established tumors at a distant site in the groups receiving HSV-1716 infected cells showed no difference in size versus control, suggesting absence of a vaccine effect.

Conclusions. We conclude that HSV-1716 may provide a oncolytic therapy for lung cancer even in the absence of immune system induction and a "carrier" cell could potentially deliver this vector.

This article has been cited by other articles:

				L. BRAIDWOOD, P. D. DUNN, S. HARDY, T.R. J. EVANS, and S. M. BROWN Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy Anticancer Res, June 1, 2009; 29(6): 2159 - 2166. [Abstract] [Full Text] [PDF]

				S. A. Ali, J. Lynam, C. S. McLean, C. Entwisle, P. Loudon, J. M. Rojas, S. E. B. McArdle, G. Li, S. Mian, and R. C. Rees Tumor Regression Induced by Intratumor Therapy with a Disabled Infectious Single Cycle (DISC) Herpes Simplex Virus (HSV) Vector, DISC/HSV/Murine Granulocyte-Macrophage Colony-Stimulating Factor, Correlates with Antigen-Specific Adaptive Immunity J. Immunol., April 1, 2002; 168(7): 3512 - 3519. [Abstract] [Full Text] [PDF]